/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Aldeyra Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$4.87 0(0%) ALDX at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 4.72
Highest Today 5.04
Today’s Open 4.97
Prev. Close 4.87
52 Week High 7.20
52 Week Low 1.14
Day’s Range: Low 4.72 High 5.04
52-Week Range: Low 1.14 High 7.20
1 day return -
1 Week return -11.22
1 month return -1.21
3 month return -12.02
6 month return +96.56
1 year return -2.11
3 year return -24.69
5 year return -32.52
10 year return -

Institutional Holdings

Knoll Capital Management LP 9.12

Perceptive Advisors LLC 6.75

BlackRock Inc 6.42

Vanguard Group Inc 5.83

Ardsley Advisory Partners 3.41

Vanguard Total Stock Mkt Idx Inv 2.90

AQR Capital Management LLC 2.45

iShares Russell 2000 ETF 2.23

Kingdon Capital Management LLC 2.22

Geode Capital Management, LLC 1.91

683 Capital Management LLC 1.80

State Street Corp 1.76

Morgan Stanley - Brokerage Accounts 1.29

Dimensional Fund Advisors, Inc. 1.20

Kennedy Capital Management Inc 1.14

Jacobs Levy Equity Management, Inc. 1.06

Fidelity Small Cap Index 0.91

D. E. Shaw & Co LP 0.81

Vanguard Institutional Extnd Mkt Idx Tr 0.80

Northern Trust Corp 0.67

iShares Russell 2000 Growth ETF 0.67

Wells Fargo & Co 0.61

Kennedy Micro Cap 0.57

Vanguard Explorer Inv 0.55

Deutsche Bank AG 0.51

DWS ESG Biotech LC 0.44

Woodstock Corp 0.44

Kennedy Extended Small Cap 0.44

Vanguard Russell 2000 ETF 0.43

PFG Investments, LLC 0.43

Kennedy Small Cap Select 0.41

Fidelity Extended Market Index 0.39

DFA US Small Cap I 0.32

State St Russell Sm Cap® Indx SL Cl I 0.31

DFA US Micro Cap I 0.28

RBC Private U.S. Small-Cap Eqty Pool F 0.27

Vanguard Health Care ETF 0.25

Schwab Small Cap Index 0.23

NT R2000 Index Fund - NL 0.22

iShares Micro-Cap ETF 0.20

Market Status

Strong Buy: 5

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 292.99 M

PB Ratio 6.695

PE Ratio 0.0

Enterprise Value 256.10 M

Total Assets 104.61 M

Volume 1496340

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-45691710 -45.7M, FY22:-61369285 -61.4M, FY21:-59254195 -59.3M, FY20:-37553729 -37.6M, FY19:-60826831 -60.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-63683 -0.1M, Q2/2025:-62282 -0.1M, Q1/2025:-60912 -0.1M, Q3/2024:null 0.0M, Q2/2024:-61631 -0.1M

Quarterly Net worth Q3/2025:-7688341 -7.7M, Q2/2025:-9767312 -9.8M, Q1/2025:-9929501 -9.9M, Q3/2024:-15112983 -15.1M, Q2/2024:-16847572 -16.8M

Fund house & investment objective

Company Information Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Organisation Biotechnology

Employees 8

Industry Biotechnology

CEO Dr. Todd C. Brady M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow